Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLUE Monte Rosa Therapeutics

Closed Mourning Day 01-08 16:00:00 EST

5.99

-0.53

-8.20%

盘后6.11

+0.12+2.00%

19:50 EST

High6.48	Low5.98	Vol932.75K
Open6.42	D1 Closing6.53	Amplitude7.59%
Mkt Cap368.00M	Tradable Cap221.35M	Total Shares61.44M
T/O5.80M	T/O Rate2.52%	Tradable Shares36.95M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"GLUE","market":"US","secType":"STK","nameCN":"Monte Rosa Therapeutics","latestPrice":5.99,"timestamp":1736370000000,"preClose":6.525,"halted":0,"volume":932747,"hourTrading":{"tag":"盘后","latestPrice":6.11,"preClose":5.99,"latestTime":"19:50 EST","volume":18540,"amount":111085.065,"timestamp":1736383843652},"delay":0,"floatShares":36954081,"shares":61436116,"eps":-1.765395,"marketStatus":"Closed Mourning Day","change":-0.535,"latestTime":"01-08 16:00:00 EST","open":6.42,"high":6.475,"low":5.98,"amount":5795453.724546,"amplitude":0.075862,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.765395,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1736499600000},"marketStatusCode":7,"adr":0,"listingDate":1624507200000,"exchange":"NASDAQ","adjPreClose":6.525,"preHourTrading":{"tag":"盘前","latestPrice":6.69,"preClose":6.525,"latestTime":"04:08 EST","volume":100,"amount":669,"timestamp":1736327322403},"postHourTrading":{"tag":"盘后","latestPrice":6.11,"preClose":5.99,"latestTime":"19:50 EST","volume":18540,"amount":111085.065,"timestamp":1736383843652},"volumeRatio":0.7893652713293003,"impliedVol":1.467,"impliedVolPercentile":0.5714},"requestUrl":"/m/hq/s/GLUE/tweets","defaultTab":"tweets","newsList":[{"id":"2501923801","title":"Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2501923801","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501923801?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:00","pubTimestamp":1736164800,"startTime":"0","endTime":"0","summary":"BOSTON, Jan. 06, 2025  -- Monte Rosa Therapeutics, Inc. , a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 5:15 p.m. PST.A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/monte-rosa-therapeutics-present-43rd-120000102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1720051108.HKD","IE00BZ1G4Q59.USD","BK4585","LU1162221912.USD","LU0314104364.USD","LU0912757837.SGD","LU2023251221.USD","LU2089283258.USD","LU1732799900.SGD","BK4588","BK4139","LU1989772923.USD","LU0267386448.USD","GLUE","LU1074936037.SGD","LU0098860793.USD","LU2089284900.SGD","BK4127","LU1548497426.USD","LU1363072403.SGD","LU2271345857.HKD","BK4581","LU0795875169.SGD","BK4534","LU0971096721.USD","BK4516","LU1732800096.USD","BK4137","LU0158827948.USD","LU2028103732.USD","LU1989772840.SGD","IE00BKVL7J92.USD","LU0320765646.SGD","HCSG","LU0158827781.USD","BK4504","LU0006306889.USD","LU1720051017.SGD","LU0106831901.USD","LU2347655156.SGD","LU2111349929.HKD","LU0106261372.USD","BK4539","LU0795875086.SGD","LU2357305700.SGD","LU0225283273.USD","LU1668664300.SGD"],"gpt_icon":0},{"id":"2493765825","title":"Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term","url":"https://stock-news.laohu8.com/highlight/detail?id=2493765825","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493765825?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:49","pubTimestamp":1734958140,"startTime":"0","endTime":"0","summary":"Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease mechanisms and develop tests, therapies and technologies to advance personalized medicine.Companies in synthetic biology, engineer biological systems for practical applications, including pharmaceuticals and agriculture, using genetic engineering and biotechnology techniques to design novel organisms and processes. The promise of curing genetic diseases and extending human lifespan positions these industries for substantial growth.We recommend five small and mid-sized Genomics & Synthetic Biology stocks with a favorable Zacks Rank that are set to skyrocket in near future. These stocks are: CRISPR Therapeutics AG CRSP, Immunocore Holdings plc IMCR, Monte Rosa Therapeutics Inc. GLUE, Rigel Pharmaceuticals Inc. RIGL and Castle Biosciences Inc. CSTL.Pros and Cons of Genomics & Synthetic Biology Space. Genomics enables tailored treatments to individuals based on their geneti","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/buy-5-genomics-synthetic-biology-124900313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861558580.USD","BK4139","RIGL","BK4196","CSTL","LU1861559042.SGD","BK4556","IMCR","BK4585","BK4539","CRSP","BK4505","GLUE","BK4588"],"gpt_icon":1},{"id":"2492122446","title":"Wells Fargo Downgrades Monte Rosa Therapeutics to Equalweight From Overweight, Cuts Price Target to $11 From $14","url":"https://stock-news.laohu8.com/highlight/detail?id=2492122446","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492122446?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:53","pubTimestamp":1734612791,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) has an average rating of buy and mean price target of $15.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GLUE"],"gpt_icon":0},{"id":"2491329666","title":"Monte Rosa Therapeutics Appoints DR. Eric a. Hughes to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2491329666","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491329666?lang=en_us&edition=fundamental","pubTime":"2024-12-13 20:00","pubTimestamp":1734091200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nTUA6QRCZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","GLUE","BK4139"],"gpt_icon":0},{"id":"2491329672","title":"Press Release: Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2491329672","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491329672?lang=en_us&edition=fundamental","pubTime":"2024-12-13 20:00","pubTimestamp":1734091200,"startTime":"0","endTime":"0","summary":"BOSTON, Dec. 13, 2024  -- Monte Rosa Therapeutics, Inc. , a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors. Dr. Hughes is currently Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceuticals and brings decades of biopharmaceutical industry leadership experience to Monte Rosa.\"I am very excited to welcome Dr. Eric Hughes to the Monte Rosa Board of Directors,\" said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. \"Eric brings extensive experience building and leading highly productive R&D organizations and shepherding important new therapeutics through clinical development to improve the lives of patients. In light of our expansion into new disease areas, in particular immunology and inflammation, he will be a tremendous asset to our organization as we continue to advance and expand our pipeline of d","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4139","BK4588","TM","03160","GLUE","BK4585","BK4099","BK4539"],"gpt_icon":0},{"id":"2490620859","title":"Monte Rosa Therapeutics Preclinical Trial of Potential Breast Cancer Therapy Shows Less Toxicity, Tumor Regression","url":"https://stock-news.laohu8.com/highlight/detail?id=2490620859","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490620859?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:48","pubTimestamp":1733921306,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics  said Wednesday that data from a preclinical trial of its drug MRT-9643 as a potential treatment for HR-positive/HER2-negative breast cancer has superior selectivity relative to other clinical-stage cyclin-dependent kinase 2 inhibitors and induced robust downstream CDK2 pathway suppression.MRT-9643 drove deep tumor regression in preclinical cellular models of HR-positive/HER2-negative breast cancer when combined with current standard of care therapies, the company said.\"Our results demonstrate that MRT-9643 is a highly selective oral CDK2 degrader that could potentially avoid many of the dose-limiting toxicities associated with less selective CDK2 inhibitors,\" Chief Scientific Officer Sharon Townson said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GLUE","BK4539","BK4139"],"gpt_icon":1},{"id":"2490596338","title":"Monte Rosa Closes Global License Agreement With Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2490596338","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490596338?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:45","pubTimestamp":1733921115,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics  said Wednesday it has closed its development and commercialization license deal with Novartis  for VAV1-directed molecular glue degraders, including MRT-6160.Under the terms, Novartis will attain rigths to develop, produce, and commercialize MRT-6160 and other VAV1 molecular glue degraders, Monte Rosa added.Novartis will carry out the phase 2 clinical trials, while Monte Rosa is in charge of completing the current phase 1 clinical study of MRT-6160, Monte Rosa said.The clinical-stage biotechnology company will receive a $150 million upfront payment from Novartis, it said, adding that it will co-fund phase 3 development and share any profits and losses from the production and commercialization of MRT-6160 in the US.Monte Rosa is also eligible for up to $2.1 billion in development, regulatory and sales milestones after initiation of phase 2 studies. It can also earn tiered royalties on ex-US sales.The agreement was first announced in October.Shares of Monte Rosa ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0211331839.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE0009355771.USD","BK4532","GLUE","IE00BJT1NW94.SGD","BK4578","BK4539","BK4585","BK4588","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4139","IE00BJJMRZ35.SGD","BK4007","NVS"],"gpt_icon":1},{"id":"2490855493","title":"Monte Rosa announces closing of global license agreement with Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2490855493","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490855493?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:11","pubTimestamp":1733919102,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) announced the closing of the Company’s previously announced global exclusive development and commercialization licen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monte-rosa-announces-closing-of-global-license-agreement-with-novartis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monte-rosa-announces-closing-of-global-license-agreement-with-novartis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE","BK4539","BK4139"],"gpt_icon":0},{"id":"2490175855","title":"Monte Rosa Therapeutics presents preclinical data on CDK2 degrader","url":"https://stock-news.laohu8.com/highlight/detail?id=2490175855","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490175855?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:11","pubTimestamp":1733919066,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) announced the company will present preclinical data on the potential of its highly selective cyclin-dependent kinase...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-presents-preclinical-data-on-cdk2-degrader?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-presents-preclinical-data-on-cdk2-degrader?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","GLUE"],"gpt_icon":0},{"id":"2490853276","title":"Monte Rosa Therapeutics Announces Closing of Global License Agreement With Novartis to Advance T and B Cell-Modulating Vav1-Directed Molecular Glue Degraders","url":"https://stock-news.laohu8.com/highlight/detail?id=2490853276","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490853276?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:00","pubTimestamp":1733918401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nTUA3WZZKF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","GLUE","BK4139"],"gpt_icon":0},{"id":"2490855779","title":"Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2490855779","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490855779?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:00","pubTimestamp":1733918400,"startTime":"0","endTime":"0","summary":"CDK2-directed MGD drove deep tumor regression in preclinical models of HR-positive/HER2-negative breast cancer when combined with either a CDK4/6 inhibitor or a CDK4/6 inhibitor and endocrine therapy ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/11/2995243/0/en/Monte-Rosa-Therapeutics-Presents-Preclinical-Data-at-the-2024-San-Antonio-Breast-Cancer-Symposium-on-the-Potential-of-its-CDK2-directed-Molecular-Glue-Degraders-to-Treat-HR-positiv.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLUE","HR","BK4203","BK4225","BK4539"],"gpt_icon":0},{"id":"2490855277","title":"Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders","url":"https://stock-news.laohu8.com/highlight/detail?id=2490855277","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490855277?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:00","pubTimestamp":1733918400,"startTime":"0","endTime":"0","summary":"BOSTON, Dec.  11, 2024  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/11/2995244/0/en/Monte-Rosa-Therapeutics-Announces-Closing-of-Global-License-Agreement-with-Novartis-to-Advance-T-and-B-Cell-modulating-VAV1-directed-Molecular-Glue-Degraders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLUE","BK4539"],"gpt_icon":0},{"id":"2489404562","title":"Analysts’ Top Healthcare Picks: Insulet (PODD), Monte Rosa Therapeutics (GLUE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489404562","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489404562?lang=en_us&edition=fundamental","pubTime":"2024-12-06 17:50","pubTimestamp":1733478611,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insulet (PODD – Research Report) and Monte Rosa Ther...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-insulet-podd-monte-rosa-therapeutics-glue?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-insulet-podd-monte-rosa-therapeutics-glue?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","BK4082","BK4588","PODD","GLUE","BK4585","BK4566","BK4551","HCSG","BK4539"],"gpt_icon":0},{"id":"2489458560","title":"Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2489458560","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489458560?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:11","pubTimestamp":1733400696,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) reported an update from its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-provides-development-progress-on-ongoing-mrt-2359-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-provides-development-progress-on-ongoing-mrt-2359-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4230","BK4139","BK4539","GLUE","MRT"],"gpt_icon":0},{"id":"2489804430","title":"Monte Rosa Therapeutics Provides Development Progress Update for Ongoing Mrt-2359 Phase 1/2 Study in Patients With Myc-Driven Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2489804430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489804430?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:00","pubTimestamp":1733400000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nTUA8C6DMF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLUE","BK4539"],"gpt_icon":0},{"id":"2489305184","title":"Monte Rosa Therapeutics Inc: Additional Mrt-2359 Phase 1/2 Study Clinical Results, Including Biomarker and Activity Data, Anticipated in Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2489305184","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489305184?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:00","pubTimestamp":1733400000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nTUA8C6DMF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","GLUE"],"gpt_icon":0},{"id":"2489143056","title":"Monte Rosa Therapeutics Inc: Recommended Phase 2 Dose Determined as 0.5 Mg Daily at a 21 Days on, 7 Days off Drug Dosing Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2489143056","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489143056?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:00","pubTimestamp":1733400000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nTUA8C6DMF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","GLUE","BK4139"],"gpt_icon":0},{"id":"2489430915","title":"Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2489430915","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489430915?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:00","pubTimestamp":1733400000,"startTime":"0","endTime":"0","summary":"Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients. Recommended Phase 2 dose determined as 0.5 mg daily at a 21 days on, 7 days off drug dosing schedule. Additional MRT-2359 Phase 1/2 study clinical results, including biomarker and activity data, anticipated in Q1 2025. The study has enrolled patients with a diverse set of tumor types, including non-small cell lung cancer , small cell lung cancer , n","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1hBAE5qiNVdDUIOCnfQ6sA--~B/aD0xMTQyO3c9NDE2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/a8578031236fef7f415e1357262f9cf4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1hBAE5qiNVdDUIOCnfQ6sA--~B/aD0xMTQyO3c9NDE2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/a8578031236fef7f415e1357262f9cf4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/monte-rosa-therapeutics-provides-development-120000514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4092","BK4588","BK4139","IE00B7SZLL34.SGD","LU1093756168.USD","LU1721428933.USD","IE00B19Z4B17.USD","GLUE","BK4230","LU2413666699.HKD","LU2413666426.HKD","LU2065732104.USD","NE","IE00B19Z3B42.SGD","BK4533","BK4548","CRS","MTD","MYC","BK4567","LU0347712357.USD","IE0002270589.USD","MRT","BK4006","IE0031619046.USD","BK4121","IE00B7SZL793.SGD","BK4539","IE00B19Z3581.USD","IE00B66KJ199.SGD","LU1093756325.SGD","PRGS","BK4097"],"gpt_icon":0},{"id":"2488682539","title":"Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?","url":"https://stock-news.laohu8.com/highlight/detail?id=2488682539","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488682539?lang=en_us&edition=fundamental","pubTime":"2024-12-03 06:44","pubTimestamp":1733179476,"startTime":"0","endTime":"0","summary":"Shares of Monte Rosa Therapeutics  have gained 16.4% over the past four weeks to close the last trading session at $10.36, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17 indicates a potential upside of 64.1%.The mean estimate comprises six short-term price targets with a standard deviation of $2.45. While the lowest estimate of $15 indicates a 44.8% increase from the current price level, the most optimistic analyst expects the stock to surge 93.1% to reach $20. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets shoul","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wbCMwMtKIoXj_iQA0ego4g--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wbCMwMtKIoXj_iQA0ego4g--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-see-64-224436188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4539","GLUE"],"gpt_icon":0},{"id":"2486430079","title":"Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486430079","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486430079?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:00","pubTimestamp":1732622400,"startTime":"0","endTime":"0","summary":"BOSTON, Nov. 26, 2024  -- Monte Rosa Therapeutics, Inc. , a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York, NY on Tuesday, December 3, 2024, at 3:30 p.m. ET.A webcast of the fireside chat will be accessible via the “Events” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1hBAE5qiNVdDUIOCnfQ6sA--~B/aD0xMTQyO3c9NDE2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/a8578031236fef7f415e1357262f9cf4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1hBAE5qiNVdDUIOCnfQ6sA--~B/aD0xMTQyO3c9NDE2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/a8578031236fef7f415e1357262f9cf4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/monte-rosa-therapeutics-participate-piper-120000735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","HCSG","BK4139","GLUE","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monterosatx.com","stockEarnings":[{"period":"1week","weight":-0.1369},{"period":"1month","weight":-0.4127},{"period":"3month","weight":0.2376},{"period":"6month","weight":0.3866},{"period":"1year","weight":-0.2231},{"period":"ytd","weight":-0.1369}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.151834},{"month":2,"riseRate":0.666667,"avgChangeRate":0.04993},{"month":3,"riseRate":0.666667,"avgChangeRate":0.124226},{"month":4,"riseRate":0,"avgChangeRate":-0.295044},{"month":5,"riseRate":0.333333,"avgChangeRate":0.036693},{"month":6,"riseRate":0.333333,"avgChangeRate":0.028435},{"month":7,"riseRate":0.75,"avgChangeRate":0.0647},{"month":8,"riseRate":0.5,"avgChangeRate":0.131017},{"month":9,"riseRate":0.25,"avgChangeRate":-0.16729},{"month":10,"riseRate":0.75,"avgChangeRate":0.123042},{"month":11,"riseRate":0.25,"avgChangeRate":-0.030202},{"month":12,"riseRate":0.5,"avgChangeRate":0.110748}],"exchange":"NASDAQ","name":"Monte Rosa Therapeutics","nameEN":"Monte Rosa Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monte Rosa Therapeutics,GLUE,Monte Rosa Therapeutics股票,Monte Rosa Therapeutics股票老虎,Monte Rosa Therapeutics股票老虎国际,Monte Rosa Therapeutics行情,Monte Rosa Therapeutics股票行情,Monte Rosa Therapeutics股价,Monte Rosa Therapeutics股市,Monte Rosa Therapeutics股票价格,Monte Rosa Therapeutics股票交易,Monte Rosa Therapeutics股票购买,Monte Rosa Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction